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Background: Adverse drug reactions are important determinants of inpatient and outpatient 
morbidity. Thiocolchicoside is a semisynthetic derivate of naturally occurring colchicoside, 
which is largely used in humans as a centrally acting muscle relaxant. Epileptic seizures after 
thiocolchicoside intake have been reported in individuals with a history of epilepsy, acute brain 
injury or possible blood–brain barrier disruption.
Case report: We report the case of a 66-year-old male patient presenting a sudden epileptic 
seizure temporally related to the intake of thiocolchicoside for muscle contracture and pain. The 
probably causes of the seizures were thiocolchicoside intake and cerebral microhemorrhages 
attributed to cerebral amyloid angiopathy.
Discussion: Drugs only rarely cause focal seizures. Our case indicates that thiocolchicoside 
can precipitate seizures in predisposed patients, and that its use should be avoided in patients 
with brain diseases (and therefore lower seizure thresholds) or blood–brain barrier disruption. 
This information should be provided in the drug package insert.
Keywords: adverse drug reaction, thiocolchicoside, coltrax, epileptic seizure, muscle relaxant, 
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Background
Adverse drug reactions are defined as noxious, unintended or undesired effects of any 
drug used for prophylaxis, diagnosis or therapy. Such effects constitute an important 
determinant of inpatient and outpatient morbidity. According to the drug package 
insert, the main adverse effects of thiocolchicoside (Coltrax®; AventisPharma) 
are nausea, somnolence, asthenia, allergy and vasovagal reaction. It is contraindi-
cated in patient with history of drug allergy or vasovagal reaction during previous 
utilization.1
Thiocolchicoside is a semisynthetic derivate of naturally occurring colchicoside, 
which is largely used in humans as a centrally acting muscle relaxant. This compound 
also has anti-inflammatory and analgesic effects. It is an analogue of colchicine, since 
they share the same benzo(alpha)heptalenic moiety.2
The experimental use of colchicine has been shown to induce epileptic foci in rats, 
causing generalized seizures and death.3–5 The epileptogenic activity of thiocolchicoside 
occurs mainly when there are minimal lesions of the dura and arachnoid membranes.5 
Epileptic seizures in humans have also been reported in patients with a history of 
epilepsy, acute brain injury or possible blood–brain barrier disruption.6
Here, we report a case of sudden epileptic seizure temporally related to intake of 
thiocolchicoside for muscle contracture and pain.Therapeutics and Clinical Risk Management 2009:5 636
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Case report
A 66-year-old Caucasian man of Italian descent suddenly 
developed partial motor seizures of the right upper limb 
and face with speech arrest. There were three episodes of 
acute symptomatic seizures during a 12-hour period. This 
occurred after intake of thiocolchicoside for 3 days (4 mg 
bid, in a total dose of 20 mg), as prescribed for muscular 
contracture and pain. Seizures began 6 hours after the 
final dose.
He had presented one episode of severe headache 
6 months earlier, which had been investigated using 
computed tomography (CT), magnetic resonance imaging 
(MRI) and cerebrospinal fluid examination, all of which 
produced normal results.
As co-morbidity, he had been suffering from diabetes 
mellitus, controlled with metformin (850 mg bid), for 
10 years. He had no history of epileptic seizures.
The results of the neurological examination were 
normal.
The thiocolchicoside was discontinued, and phenytoin 
anticonvulsive therapy was instituted. The seizures were thus 
controlled, and there were no further episodes.
An additional MRI scan was ordered. The new scan 
revealed three areas of microhemorrhage in the left frontal, 
right frontal and left occipital lobes, the last presenting local 
signs of gadolinium enhancement. We reviewed the MRI 
scan taken 6 months prior and observed that the microhemor-
rhages in the right frontal and left occipital lobes had been 
present at that time. A single photon emission computed 
tomography scan of the brain showed focal cortical hyper-
perfusion in left frontal lobe. Electroencephalography and 
angiography findings were normal.
The results of thorough laboratory testing (cell counts; 
glucose level; erythrocyte sedimentation rate; serum levels 
of protein, Na, K, Ca, Mg, P, alanine aminotransferase, 
aspartate aminotransferase, gamma-glutamyl transpeptidase, 
alkaline phosphatase and bilirubin; coagulation tests; creatine 
kinase level; urea nitrogen level; creatinine level; autoanti-
body titers; complement activation; and urine exam) were 
normal.
Cerebral microhemorrhages were imputed to cerebral 
amyloid angiopathy (CAA),7 which, together with the thio-
colchicoside treatment, constituted the probably cause of 
the seizures.
Phenytoin had to be changed to oxcarbazepine due to 
an elevation in liver enzyme levels. Anticonvulsive therapy 
was maintained for 6 months and then discontinued. 
At 9 months after the initial episode, the patient was not 
taking anticonvulsive drugs and had not experienced 
any additional seizures.
Discussion
This is the fourth case reported in the literature in which 
a relationship between seizures and thiocolchicoside was 
demonstrated.6 The three other cases occurred in Italy (our 
patient was of Italian descent), and this is the second case in 
which there was no history of seizures. In the two cases in 
which there was a history of epilepsy, the patients had been 
seizure-free for 7 and 9 years, respectively, and presented 
disease exacerbations only after thiocolchicoside intake. 
The other case in which there was no such history was in a 
40-year-old male patient who had been in a traffic accident 
and presented CT-proven cerebral contusion of the left hemi-
sphere. Intramuscular thiocolchicoside was administered 
(4 mg bid). Approximately 30 minutes after the second daily 
injection, the patient had a generalized tonic–clonic seizure.
The mechanism of action of thiocolchicoside is only 
partially understood. Previous studies have suggested that 
it has an agonist interaction with spinal-strychnine-sensitive 
receptors that could mediate its myorelaxant effect,8 although 
such interaction does not readily explain how it might induce 
seizures.6 Another study demonstrated a pharmacological 
profile indicating a preferential interaction of this compound 
with a cortical subtype of the gamma-aminobutyric acid type 
A (GABAA) receptor that expresses low-affinity binding sites 
for GABA. The low-affinity recognition site seems to be an 
antagonist-binding site, a finding that can readily explain the 
powerful convulsant effect of thiocolchicoside observed in 
some humans.6,9
The convulsant potential of thiocolchicoside is likely 
to involve an overwhelming effect of drug antagonism at a 
subset of GABAA receptors over the drug inhibitory effect 
of allosteric activation of strychnine-sensitive glycine 
receptors.5 Another study provided molecular evidence that 
the epileptogenic activity of thiocolchicoside might be due 
to inhibition of the function of inhibitory receptors in the 
central nervous system.10
Thiocolchicoside induced epileptic seizures and even 
death in rats that received this drug parentally, at the dosage 
of 6 to 12 mg/kg, although only in rats that had minimal 
lesions of the dura and arachnoid membranes.5 Our patient 
weighed 80 kg and presented seizures when treated with a 
much lower dose (0.25 mg/kg for the cumulative dose or 
0.05 mg/kg for a single dose).
In our case, the patient had cerebral microhemorrhages, 
consistent with cerebral amyloid angiopathy (CAA),7 which Therapeutics and Clinical Risk Management 2009:5
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accounts for the majority of primary lobar intracerebral 
hemorrhage in the elderly.11 The presence of multiple, strictly 
lobar hemorrhages (including microhemorrhages) detected 
in MRI sequences has been shown to be highly specific 
for severe CAA in elderly patients presenting no other 
definitive cause of intracerebral hemorrhage, such as trauma, 
ischemic stroke, tumor, hypertension, coagulopathy, excessive 
use of anticoagulants or vasculitis.12,13 Gradient-echo or 
T2*-weighted MRI is a technique that is highly sensitive in the 
detection of old and recent cerebral hemorrhage.12,13 This test 
is capable of detecting millimeter-sized paramagnetic blood 
products (including hemosiderin) in the brain parenchyma. 
Since hemosiderin remains stored at sites of previous 
bleeding, hemorrhagic burden can be assessed over time.
For at least 6 months prior to the seizure, our patient had 
presented intracerebral microhemorrhages probably due to 
amyloid angiopathy. Thiocolchicoside might have lowered 
the seizure threshold and precipitated the acute symptomatic 
seizure.
Drugs only rarely cause focal seizures. Our case, as do the 
other three described before, indicates that thiocolchicoside 
can precipitate seizures in predisposed patients and should be 
avoided in patients with brain diseases (and therefore lower 
seizure thresholds) or blood–brain barrier disruption. This 
information should be included in the drug package insert.
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